Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,186 recruiting studies in this area right now.
By phase
- Not applicable2,938
- Phase 2757
- Phase 1542
- Phase 3381
- Phase 1/Phase 2295
- Phase 4211
- Phase 2/Phase 362
Top conditions
- Breast Cancer1,226
- Melanoma184
- Rheumatoid Arthritis141
- Metastatic Breast Cancer140
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Breast Neoplasms120
- Triple Negative Breast Cancer117
- Colorectal Cancer93
- Ovarian Cancer92
- Psoriasis88
- Breast Carcinoma83
- Lung Cancer78
- Prostate Cancer70
- Rheumatoid Arthritis (RA)64
- Diabetic Foot Ulcer61
- Systemic Sclerosis60
- Cancer58
Leading sponsors
- Fudan University65
- M.D. Anderson Cancer Center52
- Memorial Sloan Kettering Cancer Center50
- Novartis Pharmaceuticals49
- Mayo Clinic42
- Assistance Publique - Hôpitaux de Paris41
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University37
- AstraZeneca36
- National Cancer Institute (NCI)35
- Second Affiliated Hospital, School of Medicine, Zhejiang University30
Where studies are running
- California416
- Arizona160
- Florida132
- Alabama130
- New York110
- Texas106
- Massachusetts93
- Maryland91
- Pennsylvania76
- North Carolina69
Recruiting studies5,186 total
- NCT07780929Recruiting
Study of XJH05 ointment for mild-to-moderate plaque psoriasis
This trial tests a new ointment (XJH05) for people with mild-to-moderate plaque psoriasis. It aims to see if this treatment helps reduce symptoms and is safe for topical use.
Xi'an, ShaanxiAges 18–65 - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Duarte, CaliforniaAges 18 years+ - NCT07783243Recruiting
Leishmaniasis vaccine response study in Ethiopia
This study tests how your immune system responds to parts of a potential vaccine for leishmaniasis. Doctors will take small blood or skin samples to see if your body's cells react to these vaccine pieces, which could help design a better vaccine in the future.
Addis AbabaAges 18–65 - NCT07060807RecruitingPhase 3
Study of Patritumab Deruxtecan for Advanced HR+/HER2- Breast Cancer
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
Daphne, AlabamaAges 18 years+ - NCT07710443Recruiting
Mosaic Filler Trial for Midface Volume Loss
This trial tests a new cheek filler called Mosaic for people with moderate to severe cheek volume loss. It helps doctors see if Mosaic is safe and effective for filling out the midface area.
Bradenton, FloridaAges 22 years+ - NCT07743190RecruitingPhase 2
Lighter chemo for early-stage triple-negative breast cancer with high immune cells
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
Syracuse, New YorkAges 18 years+ - NCT07412704RecruitingPhase 1/Phase 2
Study of BMS-986528 for hard-to-treat rheumatoid arthritis
This trial tests a new drug called BMS-986528 for people with rheumatoid arthritis that is difficult to treat. It aims to see if the drug can help when other treatments haven't worked well.
La Jolla, CaliforniaAges 18–65 - NCT05501704RecruitingPhase 2
Testosterone-blocking therapy for male breast cancer
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07053800RecruitingPhase 2
Obe-cel for severe lupus with kidney inflammation
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
New York, New YorkAges 12–65 - NCT07049328RecruitingPhase 1
Study of HCW9302 for Alopecia Areata
This trial tests a new drug, HCW9302, that targets the immune system to help hair regrow in people with alopecia areata (including extensive forms like totalis or universalis). It may be an option for adults who have not responded well to other treatments.
Tampa, FloridaAges 18–70 - NCT06711887RecruitingPhase 3
Long-term extension study of ianalumab for lupus nephritis
This study is a follow-up for people with lupus nephritis who already completed a 144-week treatment course with ianalumab in an earlier study. It tests whether continuing or stopping the drug is safe and effective over the long term.
Orchard Park, New YorkAges 18–100 - NCT07475572RecruitingPhase 1
Comparing a biosimilar to Keytruda for melanoma after surgery
This trial tests a biosimilar drug (AVT32-DRL_PB) to see how it compares to the approved immunotherapy Keytruda® in people whose melanoma has been fully removed by surgery. It aims to help prevent the cancer from coming back.
KievAges 18 years+ - NCT06966700RecruitingPhase 3
Study of Sac-TMT in Early High-Risk Breast Cancer
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT07504796RecruitingPhase 2
Adding ipilimumab to standard melanoma therapy based on ctDNA
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
New York, New YorkAges 18 years+ - NCT07733765RecruitingPhase 3
A Study of Ritlecitinib for Moderate Hair Loss from Alopecia Areata
This study tests if the medicine ritlecitinib can help regrow hair in people with alopecia areata, a condition that causes patchy hair loss. It's for young people and adults who have lost between 20% and 50% of their scalp hair for at least 6 months but no more than 10 years.
Encinitas, CaliforniaAges 12 years+ - NCT05440422RecruitingPhase 2
Anifrolumab for heart and blood vessel health in lupus
This trial tests whether a drug called anifrolumab can improve early signs of heart and blood vessel damage in people with lupus. It may help prevent future heart problems and strokes.
Bethesda, MarylandAges 18–80 - NCT07774507Recruiting
Daily movement and artery health in rheumatoid arthritis
This study looks at how daily movement patterns (like sitting, standing, and walking) relate to the buildup of plaque in arteries (atherosclerosis) in people with rheumatoid arthritis. It aims to understand if certain activity levels can lower heart risks.
Presidente Prudente, São PauloAges 18–65 - NCT07776951Recruiting
Physical activity for breast cancer patients during treatment
This study tests whether a supervised physical activity program can help breast cancer patients reduce inflammation and improve health during neoadjuvant treatment (chemotherapy or immunotherapy given before surgery). The goal is to see if exercise can improve treatment outcomes and overall well-being.
MilanAges 18 years+ - NCT07776301Recruiting
One-stop radiation therapy for breast cancer using a CT-Linac machine
This study tests a faster, all-in-one radiation therapy approach for breast cancer using a CT-Linac machine. It aims to make treatment more convenient and may be an option if you need radiation before, after, or instead of surgery.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07776613RecruitingPhase 2
Bone strengthening drug for breast cancer with osteoporosis
This study tests a new drug called romosozumab, which may help strengthen bones and reduce fractures in people with breast cancer that has spread to the bones and who also have osteoporosis. If you are on hormone therapy and have weak bones, this could help protect your bones.
Basking Ridge, New JerseyAges 18 years+ - NCT07777783Recruiting
Non-surgical treatment for breast abscess
This study tests whether draining a breast abscess with a needle and using antibiotics can treat it without surgery. It may be a gentler option for women with this condition.
SohagAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT07203378RecruitingPhase 2
Exercise program for energy and zest on Enhertu
This study tests whether a supervised exercise program can help reduce fatigue and improve energy for people with breast cancer who are taking the drug Enhertu. You would do both aerobic and resistance exercises over several weeks.
Salt Lake City, UtahAges 18 years+ - NCT05799378RecruitingPhase 3
Stopping hydroxychloroquine in older adults with stable lupus
This study looks at whether it is safe for people aged 55 and older with long-standing, stable lupus to stop taking hydroxychloroquine (a medicine that helps control lupus) without their disease flaring up. If you have been taking this medicine for at least 7 years and your lupus has been quiet for a while, you may be able to join.
Los Angeles, CaliforniaAges 55 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,186 recruiting dermatology studies from the U.S. registry right now, out of 8,234 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.